Drug Feared to be Defective Will be Phased Out

Rick Patterson

Attorney

0 CommentsPrint ArticleSubscribe

Today, the U.S. Food and Drug Administration (FDA) announced that the drug maker has agreed to a marketing suspension of Trasylol. It has come to the attention of the FDA that a Canadian study suggests there is an increased risk of death to the patient with the use of the drug.

Trasylol is what is known as an antifibrinolytic drug. Antifibrinolytic drugs help slow the breakdown of blood clots and subsequent excessive bleeding. Trasylol is aimed at preventing blood loss in patients with an increased risk for blood loss during heart bypass surgery. Currently the are not a lot of options for patients at risk for excessive bleeding during heart surgery. As a result, the FDA and Bayer will phase Trasylol out of the marketplace. In the meantime, the risk versus benefits of taking Trasylol will have to be determined after a thorough study has been completed.

Additional information pertaining to defective and dangerous drugs